The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)
Open accessAbstract
CDK2 inhibitors have been proposed as effective anti‐cancer therapeutics. We show here that CYC202 (R‐roscovitine) is a potent inhibitor of recombinant CDK2/cyclin E kinase activity (IC 50 = 0.10 μM) with an average cytotoxic IC 50 of 15.2 μM in a panel of 19 human tumour cell lines, and we also demonstrate selectivity for rapidly proliferating cells over non‐proliferating cells. A study of the cell cycle effects of CYC202 in Lovo colorectal carcinoma cells showed that the major effect was not the predicted arrest in one part of the cycle, but rather an induction of cell death from all compartments of the cell cycle. The maximum tolerated dose given intravenously to mice was in excess of 20 mg/kg. Doses up to 2,000 mg/kg were tolerated when administered orally in mice. Following repeated intraperitoneal administration (3 times daily for 5 days) of 100 mg/kg to nude mice bearing the Lovo human colorectal tumour, CYC202 induced a significant antitumour effect with a 45% reduction in tumour growth compared to controls. A second experiment using the human uterine xenograft MESSA‐DX5 treated with orally administered CYC202 (500 mg/kg 3 times daily for 4 days) also exhibited a significant reduction in the rate of growth of the tumour (62%). These data, showing enzyme and cellular potency together with antitumour activity, confirm the potential of CDK2 inhibitors such as CYC202 as anticancer drugs. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Morgan, D. O. (1995) · Nature · doi:10.1038/374131a0 · Cited by 3,284
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Graña, X., & Reddy, E. P. (1995) · PubMed · Cited by 1,139
De Azevedo, W. F., Leclerc, S., Meijer, L., Havlicek, L., Strnad, M., & Kim, S. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.0518a.x · Cited by 729
(1998) · British Journal of Cancer · doi:10.1038/bjc.1998.1 · Cited by 654
Inhibition of Cyclin‐Dependent Kinases by Purine Analogues
Veselý, J., Havliček, L., Strnad, M., Blow, J. J., Donella‐Deana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., Leclerc, S., et al. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.00771.x · Cited by 632
Trends in cancer incidence and mortality in Scotland: description and possible explanations
Swerdlow, A., dos Santos Silva, I., Reid, A., Qiao, Z., Brewster, D., & Arrundale, J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.424 · Cited by 532
Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.
Shah, M. A., & Schwartz, G. K. (2001) · PubMed · Cited by 450
Relationship of CDK-activating kinase and RNA polymerase II CTD kinase TFIIH/TFIIK
Feaver, W. J., Svejstrup, J. Q., Henry, N. L., & Kornberg, R. D. (1994) · Cell · doi:10.1016/0092-8674(94)90040-x · Cited by 426
The Prognostic Significance of Altered Cyclin-Dependent Kinase Inhibitors in Human Cancer
Tsihlias, M., Kapusta, M., & Slingerland, M. (1999) · Annual Review of Medicine · doi:10.1146/annurev.med.50.1.401 · Cited by 319
Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
Chen, Y.-N. P., Sharma, S. K., Ramsey, T. M., Jiang, L., Martin, M. S., Baker, K., Adams, P. D., Bair, K. W., & Kaelin, W. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4325 · Cited by 314
Soussi, T., Dehouche, K., & B�roud, C. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200001)15:1<105::aid-humu19>3.0.co;2-g · Cited by 271
Havlíček, L., Hanuš, J., Veselý, J., Leclerc, S., Meijer, L., Shaw, G., & Strnad, M. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960666x · Cited by 243
Plasma Membrane Alterations and Cytoskeletal Changes in Apoptosis
van Engeland, M., Kuijpers, H. J. H., Ramaekers, F. C. S., Reutelingsperger, C. P. M., & Schutte, B. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3738 · Cited by 200
Drosophila Cdk4 is required for normal growth and is dispensable for cell cycle progression
Meyer, C. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.17.4533 · Cited by 186
Lu, H., Fisher, R. P., Bailey, P., & Levine, A. J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.10.5923 · Cited by 172
Cellular effects of olomoucine, an inhibitor of cyclin‐dependent kinases
Abraham, R., Acquarone, M., Andersen, A. C., Asensi, A. O., Bellé, R., Berger, F., Bergounioux, C., Brunn, G. J., Buquet-Fagot, C., Fagot, D., et al. (1995) · Biology of the Cell · doi:10.1016/0248-4900(96)81298-6 · Cited by 154
Chemical inhibitors of cyclin-dependent kinases
Meijer, L., & Kim, S. (1997) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(97)83011-x · Cited by 140
Alessi, F., Quarta, S., Savio, M., Riva, F., Rossi, L. H., Stivala, L. A., Scovassi, A. I., Meijer, L., & Prosperi, E. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4216 · Cited by 139
The Effect of the Cyclin-Dependent Kinase Inhibitor Olomoucine on Cell Cycle Kinetics
Schütte, B., Nieland, L. J. W., van Engeland, M., Henfling, M. E. R., Meijer, L., & Ramaekers, F. C. S. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3700 · Cited by 108
Edamatsu, H., Gau, C., Nemoto, T., Guo, L., & Tamanoi, F. (2000) · Oncogene · doi:10.1038/sj.onc.1203625 · Cited by 107
David-Pfeuty, T. (1999) · Oncogene · doi:10.1038/sj.onc.1203103 · Cited by 87
Legraverend, M., Ludwig, O., Bisagni, É., Leclerc, S., Meijer, L., Giocanti, N., Sadri, R., & Favaudon, V. (1999) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(99)00064-4 · Cited by 58
Cited by
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Metadata
- Authors
- McClue, S. J., Blake, D., Clarke, R., Cowan, A., Cummings, L., Fischer, P. M., MacKenzie, M., Melville, J., Stewart, K., Wang, S., Zhelev, N., Zheleva, D., & Lane, D. P.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2002-10-09
- Volume
- 102
- Issue
- 5
- Pages
- 463-468
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2039771541
- Cited by
- 364
- References
- 24
- FWCI
- 9.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.